Genetic Testing in Pain Management: Evaluating the Evidence

Pharmacogenetic testing for pain management is increasingly available. The pitch is compelling: a simple cheek swab that promises to predict which medications will work best for each injured worker, potentially reducing trial-and-error prescribing and improving outcomes. Beneath the marketing materials lies a more complicated reality.

The key question is not whether a laboratory can identify genetic variants, but whether those results improve prescribing decisions, patient safety, functional recovery, or overall outcomes.

The Science Behind the Testing

Pharmacogenetic testing analyzes genetic variations that affect how the body metabolizes medications. The most tested gene in pain management is CYP2D6, the gene that encodes the CYP2D6 enzyme, a protein responsible for metabolizing several opioids including codeine and tramadol. This gene-enzyme distinction matters: it is the enzyme that acts on the drug, and the gene that determines how much functional enzyme a patient produces.^[1] People can be classified as poor, intermediate, normal, or ultrarapid metabolizers based on their CYP2D6 genetic variants.

A poor metabolizer taking codeine will produce significantly less of the active metabolite (morphine), resulting in reduced pain relief.^[2] Conversely, an ultrarapid metabolizer might experience dangerous toxicity from standard doses; a risk serious enough that the FDA added a boxed warning to codeine products in 2017 after several children died following routine post-surgical prescriptions.^[3]

The Clinical Pharmacogenetics Implementation Consortium (CPIC), a National Institutes of Health (NIH)-funded group of international experts, has published guidelines recommending that CYP2D6 poor and ultrarapid metabolizers avoid codeine and tramadol entirely.^[4] For these specific medications in these specific patient populations, genetic testing can provide valuable safety information.

Where the Evidence Gets Weaker

The challenge begins when commercial testing panels expand far beyond these well-established gene-drug pairs. Many commercially available tests screen for multiple genes including OPRM1 (opioid receptor), COMT (catechol-O-methyltransferase), and various other metabolic enzymes.^[5]

A useful framework for evaluating any diagnostic test asks three sequential questions. First, analytic validity: did the lab correctly read the DNA? Modern pharmacogenetic labs generally perform well here; technical accuracy is typically strong. Second, clinical validity: does the gene variant affect how the drug works? For CYP2D6 and codeine or tramadol, the answer is yes, and the evidence is robust; however, for many other gene-drug pairs on commercial panels, the relationship is weaker or unproven. Third, and most critically, clinical utility: does using the test result improve patient care? A test can be technically accurate and biologically plausible yet still fail to improve prescribing decisions or patient outcomes. That gap between analytic accuracy and clinical utility is where most commercial pharmacogenetic panels fall short, and where payers, adjusters and clinical reviewers should focus their scrutiny.

For many of these gene-drug combinations, clinical evidence is limited or conflicting. The 2021 CPIC opioid guidelines explicitly stated there was “insufficient or mixed evidence” for OPRM1 and COMT to support clinical recommendations, despite biological plausibility.¹ Similarly, while CYP2D6 metabolizes oxycodone and hydrocodone to more active forms, it’s unclear how important this conversion is for clinical response. CPIC does not recommend changing therapy based on genotype for these medications. ¹

What Major Payers and Guidelines Say

The gap between marketing claims and evidence-based medicine has not gone unnoticed. Multiple major insurance carriers providing group healthcare services, including Blue Cross Blue Shield, Aetna and others, classify pharmacogenetic testing for pain management as “investigational,” meaning it lacks sufficient evidence to support routine clinical use. ^1,[6]

Their conclusion? “No high-quality studies were found in the published literature that validates the use of pharmacogenetic testing for pain management. At present, the clinical utility of pharmacogenetic testing in pain management is poorly defined.”⁵

In February 2020, the FDA issued a safety communication expressing concerns about firms making claims regarding genetic testing and medication management “that are not supported by recommendations in the FDA-approved drug labeling or other scientific evidence.”^[7] The agency has since issued warning letters to laboratories making unsupported claims about their pharmacogenetic tests.

Notably, other major pain management and occupational medicine guidelines have reached similar conclusions. The CDC’s Clinical Practice Guideline for Prescribing Opioids and the American College of Occupational and Environmental Medicine (ACOEM) guidelines do not recommend routine pharmacogenetic testing as part of standard pain management. This consensus across payer, regulatory and clinical guideline bodies reflects the current state of the evidence, not a lack of scientific interest, but a recognition that clinical utility has not yet been established for broad-panel testing.

The Workers’ Compensation Context

Key Takeaways for Claims Professionals

• Pharmacogenetic testing can be expensive ($100–$300 per panel) with limited proven clinical benefit for most WC claims.
• The evidence is strongest for CYP2D6 and codeine or tramadol only — it does not reliably extend to other opioids commonly used in workers’ compensation.
• Major payers, the CDC, and ACOEM do not recommend routine pharmacogenetic testing for pain management — classifying it as investigational.
• Broad, multi-gene panels marketed for routine opioid management consistently exceed the current evidence base — scrutinize vendor claims carefully.
• The right question to ask: will this test result change how I manage this injured worker’s care in a meaningful, measurable way?

For injured workers, the situation becomes even more complex. While pharmacogenetic testing might eventually play a valuable role in personalized medicine, workers’ compensation claims present unique considerations:

1. Limited Real-World Evidence Most pharmacogenetic studies occur in controlled clinical settings. Real-world adherence, drug-drug interactions, concurrent medical conditions, and the psychosocial factors that influence pain perception in injured workers aren’t well-represented in research.[8]
2. Cost-Benefit Questions Testing typically costs between $100-300 per panel.[9] For tests with limited clinical utility, this represents pharmacy spend that might be better allocated to evidence-based interventions, medication therapy management or adherence support.
3. Inappropriate Use Risk Some panels claim to predict opioid addiction risk or provide guidance for medications with weak or no supporting evidence. In October 2022, an FDA advisory panel voted strongly against one such test (AvertD) intended to assess opioid use disorder risk, noting serious limitations in the available evidence.⁶
4. Potential for Confusion Genetic test results can be misinterpreted. A report showing someone is a CYP2D6 poor metabolizer might lead to inappropriate medication changes for drugs where that genetic variant doesn’t meaningfully impact outcomes. Not all healthcare providers have the expertise to interpret complex pharmacogenetic panels appropriately.
5. Limited Applicability to the Workers’ Compensation (WC) Opioid Population The strongest CYP2D6 evidence centers on codeine and tramadol; however, these are not the dominant long-term opioids in workers’ compensation. The WC opioid population is more likely to be using extended-release morphine, oxycodone, or fentanyl patches, medications for which the CYP2D6 evidence base is considerably weaker or nonexistent. This limits the practical reach of pharmacogenetic testing to a relatively small subset of WC claimants. Applying the science broadly across all opioid users would overstate what the evidence supports, and from an economic standpoint, the return on investment narrows considerably when the eligible patient population is this small.

When Testing Might Make Sense

This doesn’t mean pharmacogenetic testing has no role in workers’ compensation. Specific clinical scenarios where testing may provide value include:

• Treatment failures with codeine or tramadol in patients where these medications are appropriate options, genetic testing might explain why standard doses aren’t working
• Unusual toxicity or side effects with medications known to be affected by genetic variants
• Patients requiring multiple medication trials for chronic pain, particularly when psychiatric comorbidities require antidepressants that also have pharmacogenetic guidance[10]

The key is targeted use based on clinical need rather than routine, broad-panel testing of all injured workers prescribed pain medications.

A Relationship-Focused Approach

Pharmacogenetic testing should balance scientific evidence, clinical necessity and cost-effectiveness. Rather than adopting blanket approvals or denials, we recommend:

• Limiting testing to medications with strong CPIC guidance (primarily codeine and tramadol for CYP2D6)
• Requiring clinical justification that explains why testing will change management
• Ensuring providers have expertise in interpreting results appropriately
• Questioning panels that claim to predict addiction risk or provide guidance beyond established gene-drug pairs
• Considering alternative strategies like therapeutic drug monitoring when available

The promise of personalized medicine is real, and pharmacogenetics will likely play an increasing role in healthcare. For specific, well-established gene-drug pairs, primarily CYP2D6 and codeine or tramadol, testing can provide genuine clinical value in carefully selected patients. But those patients represent a small subset of the WC opioid population, and the economics of testing at scale are difficult to justify when the applicable patient population is this narrow. Broad, multi-gene panels marketed for routine pain management consistently exceed the current evidence base. Years after pharmacogenetic testing entered the market, the clinical utility question for most opioid gene pairs remains unresolved, and that has not changed. Workers’ compensation stakeholders should approach PGx vendor claims with scrutiny, demand evidence of clinical utility rather than analytic accuracy alone, and reserve testing for the specific clinical scenarios where the science is strongest.

[1] Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888-896.

[2] Del Tredici AL. Optimizing opioid therapy with pharmacogenetics. Practical Pain Management. 2021;21(2).

[3] U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. April 20, 2017.

[4] Smith DM, Weitzel KW, Elsey AR, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med. 2019;21(8):1842-1850.

[5] BlueCross BlueShield Association. Pharmacogenetic testing for pain management. Medical Policy 2.04.131. Updated January 2025.

[6] Federal Employee Program. Pharmacogenetic testing for pain management. FEP Medical Policy Manual 2.04.131. Updated January 2025.

[7] U.S. Food and Drug Administration. The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA Safety Communication. October 31, 2018.

[8] Owusu A, Hamadeh I, Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy. 2017;37(9):1105-1121.

[9] Smith DM, Figg WD. Evidence regarding pharmacogenetics in pain management and cancer. Am Soc Clin Oncol Educ Book. 2023;43:e100173.

[10] Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191-200.